Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 1989;20:1553-1556

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mima, T.
Right arrow Articles by Masaki, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mima, T.
Right arrow Articles by Masaki, T.

Stroke, Vol 20, 1553-1556, Copyright © 1989 by American Heart Association


ARTICLES

Endothelin acts in feline and canine cerebral arteries from the adventitial side

T Mima, M Yanagisawa, T Shigeno, A Saito, K Goto, K Takakura and T Masaki
Department of Neurosurgery, University of Tokyo, Japan.

We investigated the in vivo vasoconstrictor effect of endothelin, a recently characterized vasoconstrictor peptide from vascular endothelium, in the basilar arteries of five cats and five dogs. Basilar artery caliber was angiographically measured under anesthesia before (control) and after either vertebral artery infusion or cisternal injection of the peptide. In cats, 5-500 pmol endothelin induced a dose-dependent basilar artery contraction in vivo when injected intracisternally; within 3 minutes after injection of 500 pmol endothelin, basilar artery caliber was decreased by 73 +/- 4% compared with control diameter before injection. The vasoconstriction was extremely long-lasting; no significant recovery of basilar artery caliber was observed for up to 2 hours after injection. In contrast, infusion of up to 3,000 pmol endothelin into the vertebral artery had no appreciable effect on basilar artery caliber. Similar results were obtained in dogs; vasoconstriction was maintained for as long as 12 hours. Our observations suggest that endothelin acts in cerebral vessels from the adventitial side, not from the luminal side, possibly due to the presence of the blood-arterial wall barrier. The long- lasting nature of endothelin-induced constriction of the cerebral arteries in vivo suggests that the peptide might be involved in the pathogenesis of cerebral vasospasm.


This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
C.-L. Lin, A. S. Dumont, S.-C. Wu, C.-J. Wang, S.-L. Howng, Y.-F. Huang, W.-Y. Wong, N. F. Kassell, A. Y. Jeng, and A.-L. Kwan
17{beta}-Estradiol Inhibits Endothelin-1 Production and Attenuates Cerebral Vasospasm After Experimental Subarachnoid Hemorrhage.
Experimental Biology and Medicine, June 1, 2006; 231(6): 1054 - 1057.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Sonveaux, C. Dessy, P. Martinive, X. Havaux, B. F. Jordan, B. Gallez, V. Gregoire, J.-L. Balligand, and O. Feron
Endothelin-1 Is a Critical Mediator of Myogenic Tone in Tumor Arterioles: Implications for Cancer Treatment
Cancer Res., May 1, 2004; 64(9): 3209 - 3214.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
K. Fa{beta}bender, B. Hodapp, S. Rossol, T. Bertsch, J. Schmeck, S. Schutt, M. Fritzinger, P. Horn, P. Vajkoczy, M. Wendel-Wellner, et al.
Endothelin-1 in Subarachnoid Hemorrhage : An Acute-Phase Reactant Produced by Cerebrospinal Fluid Leukocytes
Stroke, December 1, 2000; 31(12): 2971 - 2975.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Shihara, Y. Hirooka, N. Hori, I. Matsuo, T. Tagawa, S. Suzuki, N. Akaike, and A. Takeshita
Endothelin-1 increases the neuronal activity and augments the responses to glutamate in the NTS
Am J Physiol Regulatory Integrative Comp Physiol, August 1, 1998; 275(2): R658 - R665.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Roux, V. Breu, T. Giller, W. Neidhart, H. Ramuz, P. Coassolo, J. P. Clozel, and M. Clozel
Ro 61-1790, a New Hydrosoluble Endothelin Antagonist: General Pharmacology and Effects on Experimental Cerebral Vasospasm
J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1110 - 1118.
[Abstract] [Full Text]


Home page
StrokeHome page
Y. Lampl, G. Fleminger, R. Gilad, R. Galron, I. Sarova-Pinhas, and M. Sokolovsky
Endothelin in Cerebrospinal Fluid and Plasma of Patients in the Early Stage of Ischemic Stroke
Stroke, October 1, 1997; 28(10): 1951 - 1955.
[Abstract] [Full Text]